Bayer Aktiengesellschaft (BAYRY)
OTCMKTS · Delayed Price · Currency is USD
8.01
-0.18 (-2.20%)
Nov 17, 2025, 4:00 PM EST
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 9.66B EUR in the quarter ending September 30, 2025, a decrease of -3.09%. This brings the company's revenue in the last twelve months to 45.87B, down -1.87% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
45.87B EUR
Revenue Growth
-1.87%
P/S Ratio
0.59
Revenue / Employee
499.28K EUR
Employees
91,864
Market Cap
31.84B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Mid-Atlantic Home Health Network | 27.00M |
| Silence Therapeutics | 25.83M |
| China New Energy Group Co. | 12.51M |
| Nuo Therapeutics | 2.61M |
Bayer Aktiengesellschaft News
- 3 days ago - Siemens Warns Currency Headwinds Will Hit 2026 Results; CEO Defends Mid-Term Target - Benzinga
- 5 days ago - Bayer Aktiengesellschaft (BAYRY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Bayer AG (BAYRY) Q3 2025 Earnings Call Highlights: Strong EPS Growth Amid Market Challenges - GuruFocus
- 5 days ago - Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks - Benzinga
- 5 days ago - Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks - Benzinga
- 5 days ago - Q3 2025 Bayer AG Earnings Call Transcript - GuruFocus
- 5 days ago - Bayer Q3 Earnings Beat Estimates on Crop Science Business Gains - Nasdaq
- 5 days ago - Bayer Aktiengesellschaft 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha